RT期刊文章SR电子T1完全公开每周的方案:一个概念验证研究摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP 1902502 10.1183/13993003.02502 -2019签证官56是3 A1 Kort Fatma A1弗尔涅勒雷,Laure A1 Chauffour Aurelie 188bet官网地址A1 Jarlier文森特A1 Lounis,该A1安德利,柯恩A1奥布里,亚历山德拉A1 Guglielmetti,洛伦佐A1 Veziris,尼古拉斯·年2020 UL //www.qdcxjkg.com/content/56/3/1902502.abstract AB背景世界卫生组织建议监督治疗肺结核。断断续续的方案有可能简化监督提高合规。我们的目标是分析每周的冲销活动方案基于药物半衰期长,bedaquiline rifapentine,在小鼠模型的肺结核。方法300瑞士感染小鼠静脉注射感染×10−6 CFU结核分枝杆菌H37Rv。老鼠一旦每周治疗方案包含:1)bedaquiline, rifapentine和吡嗪酰胺(BPZ);2)BPZ +莫西沙星(BPZM);3)BPZM +氯法齐明(BPZMC);4)标准的日常养生肺结核。所有方案都给出4或6个月。杀菌和冲销活动进行评估。结果2个月的治疗后,意味着在肺为0.76±0.60 log10 CFU计数小鼠每日控制方案和消极的对待所有老鼠每周方案处理日常控制相比(p < 0.05)。 All mice had negative lung cultures on completion of either 4 or 6 months of treatment, whereas 3 months after 4 and 6 months of treatment, respectively, the relapse rate was 64% and 13% in the standard daily regimen, 5% and 0% in BPZ, 0% and 0% in BPMZ and 0% and 5% in BPMZC (p<0.05 for all once-weekly regimens versus 4-month daily control; p>0.05 for all once-weekly regimens versus 6-month daily control).Conclusions BPZ-based once-weekly regimens have higher sterilising activity than the standard daily regimen and could greatly simplify treatment administration and possibly shorten the duration of tuberculosis treatment.Bedaquiline–rifapentine–pyrazinamide-based once-weekly regimens have higher sterilising activity than the standard daily regimen of tuberculosis and could thus greatly simplify treatment of tuberculosis https://bit.ly/2W8yx2r